Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Global drugmakers rush to boost US presence as tariff threat looms

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Companies are investing billions in new plants and expanding existing facilities across America. These moves aim to avoid penalties and ensure supply chains remain robust. Several major pharmaceutical firms have…

The Economic Times

Eli Lilly's $2.75 Billion AI Bet on Anti-Aging Drugs Signals a Major Shift in Pharmaceutical Priorities

Eli Lilly's $2.75B AI deal with Insilico Medicine targets age-related diseases. How AI is transforming longevity drug discovery and what it means for patients.

Medical Daily

Abridge wants to be the operating system for medicine—and NVIDIA and Eli Lilly are helping build it

The $5.3 billion ambient AI startup is expanding from clinical notes into billing, drug trials, and real-time insurance claims.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA issues new kidney warning for weight loss pill

Alli was the first over-the-counter weight loss pill approved by the U.S. Food and Drug Administration

The Independent UK

Medicare Is About to Cover Weight-Loss Drugs for the First Time — Here's What the GLP-1 Bridge Program Means for Millions of Americans with Obesity

Medicare's GLP-1 Bridge launches July 1, 2026, offering eligible Part D enrollees Wegovy and Zepbound for $50/month — the first-ever Medicare coverage for obesity-specific GLP-1 drugs.

Medical Daily

Innovation in medicine is having a breakthrough moment

Recent weeks have featured a series of positive developments.

Axios

Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoarthritis pain in adults with obesity. Patients also experienced substantial weight loss. These findings were shared at an American Diabetes Association conference. Retatrutide targets multiple hormones related to obesity and…

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Phemex Expands TradFi Offering Beyond 70 Assets, Bringing Global Equities to 24/7 Crypto Markets

APIA, Samoa, June 3, 2026 /PRNewswire/ -- Phemex, a user-first crypto exchange, expands its TradFi ecosystem to 73 active assets. It includes the recent addition of several high-performance contracts, ranging from healthcare leaders Eli Lilly (LLY) and Novo Nordisk (NVO) to global semiconductor and technology powerhouses like Samsung (SAMSUNG) and…

AAP

Eli Lilly Wins Back CVS Health, Reverting Novo's Advantage

Eli Lilly and Company just secured a big win as it looks to expand GLP-1 access, mending its partnership with top pharmacy benefit manager CVS Health.

MarketBeat

US stocks today: S&P 500 and Nasdaq hit record closing highs as US and Iran agree to extend ceasefire

The S&P 500 and Nasdaq hit record closing highs as hopes of a US Iran ceasefire extension boosted sentiment. Investors also digested US inflation rising to a three-year high and weaker GDP revision. AI and tech stocks led gains, with Microsoft, Snowflake, Eli Lilly and Marvell among top movers today.

The Economic Times

Is Eli Lilly Stock Outperforming the Nasdaq?

Eli Lilly has outpaced the Nasdaq Composite over the past year, and analysts remain very confident in its longer-term trajectory.

Barchart

The $4 Billion Reason Eli Lilly Stock Is Up Today

Eli Lilly shares inch higher as the company announced three acquisitions for nearly $4 billion. Here’s why each of the three vaccine makers it’s buying is bullish for LLY stock.

Barchart

Is the End of the Obesity Epidemic Near? People Lost Up to 85 Pounds Using New Weight Loss Drug

Eli Lilly's retatrutide is a significant advance on the promising results from drugs like Ozempic and Wegovy.

Reason

New weight-loss shot appears to outperform other obesity drugs on market

Eli Lilly says participants in a sizable trial of retatrutide lost much more weight compared to other weight-loss drugs

The Guardian - US

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Super Ozempic? New weight-loss drug sees even better results in recent study

Many of the patients who tested the drug lost about 30 percent of their body weight — a loss comparable to the result of bariatric surgery

MarketBeat

From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook

Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.

The Guardian - US

Eli Lilly shares bought on Trump’s behalf as his policies benefited drug firm

Filings reveal $220m to $750m in trades on US president’s behalf in first quarter of 2026, including securities linked to largest US companies

Barchart

This Hot Weight-Loss Drug Stock May Be a Surprise Challenger

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Eli Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity

Eli Lilly halted its obesity awareness campaign in India. The nation's drug regulator cautioned the company about potential violations. The campaign aimed to reframe obesity as a chronic disease. It featured various media without naming specific products. Lilly cited regulatory uncertainty and conflicting guidance. The regulator's advisory prohibited indirect promotion…

MarketBeat

What the FDA's Latest Proposal Means for Lilly, Novo, and Hims

The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.

Barchart

Do Wall Street Analysts Like Eli Lilly Stock?

While Eli Lilly has slightly lagged behind the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Evening Standard

Wegovy maker Novo Nordisk boosted by successful weight loss pill launch

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly.

The Independent UK

Novo Nordisk shares soar as sales of Wegovy weight loss pill smash forecasts

The launch in January came amid a battle in the market with Mounjaro manufacturer Eli Lilly

MarketBeat

Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent

Eli Lilly's 2026 is off to a great start, with massive earnings and revenue beats and exciting updates about its latest GLP-1, Foundayo.

Barchart

Eli Lilly Stock Popped on Earnings. America Can’t Get Enough of Its GLP-1s.

Eli Lilly stock jumps on strong Q1 performance numbers, with its GLP-1s leading the chart.

1 2 3 4 5

People

Donald Trump

195,722 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Trump Organization

501 stories

457 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.